Country: Canada
Language: English
Source: Health Canada
SALBUTAMOL (SALBUTAMOL SULFATE)
PHARMASCIENCE INC
R03CC02
SALBUTAMOL
0.4MG
SOLUTION
SALBUTAMOL (SALBUTAMOL SULFATE) 0.4MG
ORAL
250 ML
Prescription
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0108887004; AHFS:
APPROVED
2003-05-28
PRODUCT MONOGRAPH PR PMS-SALBUTAMOL ORAL LIQUID _Salbutamol Sulphate Solution _ _0.4 mg Salbutamol/mL _ Bronchodilator (beta 2 -adrenergic agonist) PHARMASCIENCE INC. Date of Revision: 6111 Royalmount Ave, Suite 100 February 5, 2015 Montréal, Québec H4P 2T4 www.pharmascience.com Control no. : 179272 _pms-SALBUTAMOL ORAL LIQUID Product Monograph _ _Page 2 of 21_ PRODUCT MONOGRAPH PR PMS-SALBUTAMOL ORAL LIQUID Salbutamol Sulphate Solution CLINICAL PHARMACOLOGY Salbutamol produces bronchodilation through stimulation of beta 2 -adrenergic receptors in bronchial smooth muscle, thereby causing relaxation of bronchial muscle fibres. This action is manifested by an improvement in pulmonary function as demonstrated by spirometric measurements. A measurable decrease in airway resistance is typically observed 30 minutes after an oral dose of salbutamol sulphate. The maximum improvement in pulmonary function usually occurs after 2 to 3 hours, and significant bronchodilator activity has been observed to persist for 6 hours or longer. INDICATIONS AND CLINICAL USE Prevention or relief of bronchospasm due to bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor. CONTRAINDICATIONS Patients who are hypersensitive to salbutamol sulphate or any of the ingredients of pms-SALBUTAMOL ORAL LIQUID. For a complete listing of ingredients, see PHARMACEUTICAL INFORMATION, COMPOSITION. Patients with tachyarrhythmias. Children 2 years of age and younger. As a tocolytic in patients at risk of premature labour or threatened abortion. _pms-SALBUTAMOL ORAL LIQUID Product Monograph _ _Page 3 of 21_ WARNINGS USE OF ANTI-INFLAMMATORY AGENTS: In accordance with the present practice for asthma treatment, concomitant anti-inflammatory therapy should be part of the regimen if salbutamol needs to be used on a regular daily basis (see DOSAGE AND ADMINISTRATION). It is essential that the physician instruct the patient in the need for further evaluation if the patien Read the complete document